Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

This study is testing two immunotherapy drugs — tiragolumab and atezolizumab — given before and after surgery in patients with newly diagnosed, surgically removable oral cavity cancer (mouth cancer) that tests positive for a marker called PD-L1. The goal is to see if immunotherapy can shrink the cancer before surgery and prevent it from coming back afterward. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Stage 3 or 4 oral cavity squamous cell carcinoma that can be surgically removed - Your tumor tests positive for PD-L1 (a protein marker) - You are in good overall health (ECOG 0–1) - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have an active autoimmune disease (other than well-controlled thyroid conditions, type 1 diabetes, or mild skin conditions) - You have had a lung inflammation condition requiring steroids - You have had a prior head and neck cancer treatment including in-field radiation - You have had a severe COVID-19 infection recently - You are pregnant or breastfeeding - You have previously received immunotherapy drugs for cancer Talk to your doctor to see if this trial is right for you.